The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1625
May 31, 2021
View Complete Issue         Table of Contents 2019 
Teprotumumab (Tepezza) for Thyroid Eye Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Teprotumumab (Tepezza) for Thyroid Eye Disease
May 31, 2021 (Issue: 1625)
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Teprotumumab (Tepezza) for Thyroid Eye Disease
Article code: 1625e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.